Table 2 Results of univariable and multivariable Cox regression models for overall survival (OS)
From: Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma
Number of patients | Overall survival time (OS; median (CI): months) | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|---|
Hazard ratio (HR) (95% CI) | p-value | Hazard ratio (HR) (95% CI) | p-value | ||||
Clinicopathological parameter | |||||||
Age | < 64 y. | 58 | 23.5 (12.6 - 33.0) | 0.626 (0.422 - 0.924) | 0.018 | 0.551 (0.350 - 0.859) | 0.008 |
> 64 y. | 60 | 13.7 (11.4 - 16.8) | |||||
Gender | Female | 53 | 20.5 (12.9 - 29.3) | 0.865 (0.587 - 1.269) | 0.459 | ||
Male | 65 | 12.6 (11.2 - 20.1) | |||||
PDAC location | Head | 93 | 19.5 (12.6 - 23.5) | 0.600 (0.384 - 0.967) | 0.036 | 0.714 (0.435 - 1.209) | 0.204 |
Body or Tail | 25 | 12.6 (10.0 - 26.4) | |||||
Tumor diameter | < 2 cm | 27 | 20.5 (11.7 - 36.5) | 0.746 (0.459 - 1.165) | 0.204 | ||
> 2 cm | 91 | 14.8 (11.9 - 20.8) | |||||
pG | 1 | 10 | 22.5 (1.5 - 33.2) | 0.89 | |||
2 | 41 | 14.8 (11.2 - 29.3) | |||||
3 | 67 | 15.9 (11.5 - 23.5) | |||||
pT | 1 | 2 | 13.4 (12.3 - 14.6) | 0.694 | |||
2 | 13 | 26.9 (9.4 - 38.8) | |||||
3 | 95 | 15.9 (11.8 - 21.0) | |||||
4 | 8 | 12.4 (1.3 - 33.0) | |||||
pN | 0 | 45 | 21.0 (14.6 - 29.3) | 0.750 (0.499 - 1.111) | 0.154 | ||
1 | 73 | 12.8 (11.7 - 17.8) | |||||
pM | 0 | 105 | 17.8 (12.9 - 23.5) | 0.569 (0.323 - 1.097) | 0.089 | 0.624 (0.166 - 1.928) | 0.427 |
1 | 13 | 11.4 (5.8 - 12.4) | |||||
pR | 0 | 91 | 16.8 (12.9 - 25.6) | 0.733 (0.474 - 1.174) | 0.19 | ||
1 | 27 | 12.4 (7.0 - 23.4) | |||||
pRM | < 1 mm | 64 | 15.4 (11.8 - 25.6) | 1.096 (0.737 - 1.622) | 0.647 | ||
> 1 mm | 50 | 16.7 (12.3 - 23.5) | |||||
PNI | 0 | 15 | 37.8 (10.6 - NA) | 0.468 (0.227 - 0.860) | 0.013 | 0.561 (0.252 - 1.115) | 0.103 |
1 | 101 | 15.9 (12.4 - 20.8) | |||||
VI | 0 | 36 | 19.7 (11.9 - 33.2) | 0.730 (0.466 - 1.115) | 0.148 | ||
1 | 76 | 12.8 (11.5 - 23.4) | |||||
LVI | 0 | 34 | 19.7 (10.6 - 33.0) | 0.877 (0.561 - 1.334) | 0.547 | ||
1 | 81 | 15 (12.3 - 21.7) | |||||
ECLNI | 0 | 69 | 20.1 (12.9 - 30.5) | 0.654 (0.437 - 0.987) | 0.043 | 0.660 (0.398 - 1.089) | 0.104 |
1 | 43 | 12.4 (10.2 - 20.8) | |||||
AJCC TNM Stage 7th Ed. | ≤ 2a | 38 | 23.5 (16.8 - 31.7) | 0.681 (0.443 - 1.023) | 0.065 | 0.672 (0.166 - 2.254) | 0.53 |
≥ 2b | 80 | 12.6 (11.4 - 16.7) | |||||
Early (pN=0,pT≤ 3,pM=0) | 38 | 23.5 (16.8 - 31.7) | Early vs LNM 0.722 (0.463 - 1.106) | Overall 0.105 | |||
pN=1,pT≤ 3,pM=0 | 62 | 14.8 (11.2 - 21.7) | LNM vs Adv 0.736 (0.425 - 1.328) | Early vs LNM 0.136 | |||
Advanced (pT=4 or pM=1) | 18 | 11.7 (6.6 - 12.4) | Early vs Adv 0.532 (0.295 - 0.997) | Early vs Adv 0.049 | |||
Adjuvant chemotherapy | 0 | 36 | 12.1 (7.0 - 16.8) | 1.337 (0.874 - 2.002) | 0.176 | ||
1 | 82 | 19.8 (13.9 - 25.6) | |||||
Molecular subtypes | |||||||
k2 | Cluster 1 | 64 | 20.9 (12.9 - 29.3) | 0.710 (0.482 - 1.048) | 0.081 | 0.247 (0.092 - 0.860) | 0.031 |
Cluster 2 | 54 | 12.7 (11.2 - 16.7) | |||||
k3 | Cluster 1 | 42 | 24.6 (16.8 - 33.2) | Cl1 vs Cl2 0.680 (0.437 - 1.050) | Overall 0.193 | Overall | 0.017 |
Cluster 2 | 50 | 12.7 (11.2 - 16.7) | Cl2 vs Cl3 1.055 (0.641 - 1.788) | Cl1 vs Cl2 0.082 | |||
Cluster 3 | 26 | 11.8 (6.6 - 20.5) | Cl1 vs Cl3 0.717 (0.426 - 1.236) | Cl1 vs Cl3 0.226 | Cl1 vs Cl3 0.209 (0.057 - 0.809) | 0.024 | |
k4 | Cluster 1 | 39 | 23.5 (14.8 - 33.0) | 0.577 | |||
Cluster 2 | 45 | 12.6 (10.6 - 16.7) | |||||
Cluster 3 | 7 | 26.2 (9.3 - 38.8) | |||||
Cluster 4 | 27 | 11.9 (6.6 - 21.0) | |||||
k5 | Cluster 1 | 41 | 23.5 (14.8 - 33.2) | Cl1 vs Cl5 0.398 (0.210 - 0.808) | Overall 0.122 | Overall | 0.271 |
Cluster 2 | 35 | 13.9 (11.4 - 21.7) | Cl2 vs Cl5 0.483 (0.251 - 0.988) | Cl1 vs Cl5 0.012 | |||
Cluster 3 | 4 | 28.9 (9.3 - NA) | Cl3 vs Cl5 0.298 (0.067 - 0.949) | Cl2 vs Cl5 0.046 | |||
Cluster 4 | 26 | 11.8 (6.6 - 20.5) | Cl3 vs Cl5 0.040 | ||||
Cluster 5 | 12 | 10 (6.9 - 16.6) | |||||